Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: the month is over as the sector closes out March and the Q1 on a high note

March 31, 2021 5:49pm

Wednesday, the sector moved to new heights pre-holiday and Thursday close

Pre-open indication results: 10 HITs and 1 MISS

The Biostage (BSTG) Chronicles: Where and WHEN is the 8-K and 10-Q coming?

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence

Numbers based facts speak better then opinion as I see answers in numbers that equate to facts!

The Dow closed DOWN -85.41 points (-0.26%); the S&P closed UP +14.34 points (+0.36%) while the Nasdaq closed UP +201.48 points (+1.54%)

Henry’omics:

The Dow slumped and the “others” Indexes rose on Wednesday as investors weighed the potential impact from President Biden’s infrastructure spending plan.

Biden will unveil a more than $2 trillion package in infrastructure spending on Wednesday. The plan would raise the corporate tax rate to 28% to fund it, an administration official told reporters Tuesday night. The White House said the tax hike, combined with measures designed to stop offshoring of profits, would fund the infrastructure plan within 15 years.

The question will be whether, investors will ‘sell into the news’ of President Biden’s infrastructure plan?

Data Docket: Private payrolls in March expanded at the fastest pace since September 2020 with companies adding 517,000 workers for the month, according to a report Wednesday from payroll processing firm ADP. It was a healthy spike from the 176,000 in February though just below the 525,000 estimates.

RegMed Investors’ (RMi) pre-open: “a mixed bag, strength is a mixed bag to sell into. Last session coming for month and Q1 in a shortened week with markets closed on Friday” … https://www.regmedinvestors.com/articles/11840

Pre-open indication results: 10 HITs <Maintain SELL: Biostage (BSTG -$0.035 with 295 shares): BUY: Applied Genetic Technologies (AGTC +$0.18), Bellicum Pharmaceuticals (BLCM +$0.38), bluebird bio (BLUE +$1.53), SELL into Strength: Athersys (ATHX +$0.16), CRISPR Therapeutics (CRSP +$6.65), Chinook Therapeutics (KDNY - $1.20), Mesoblast (MESO +$0.01), Intellia Therapeutics (NTLA +$8.01), Vericel (VCEL +$2.91)> and 1 MISS < Ionis Pharmaceuticals (IONS +$0.25)

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

Wednesday opened positive at 25/8, 1 flat and 1 acquired, stayed positive at the mid-day to 26/7, 2 flats and 1 acquired, closing positive at 29/3, 2 flat and 1 acquired;

There are clear winners and losers

Jumping with share pricing momentum: yesterday’s dogs get to bark again

Fate Therapeutics (FATE), Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) to name 5 of the 29 inclining of the 35 covered

Hammered in today’s market:

Chinook Therapeutics (KDNY), Biostage (BSTG), Voyager Therapeutics (VYGR)to name 3 of the 3 declining of the 35 covered

Key metrics:

Sector volume had LOW with 6 of the 29-upside having higher than the 3-month average volume with the volume of 1 of 3-downside having higher than the 3-month average volume;

Wednesday’s percentage (%) of the 29-upside were +0.11% (BLFS) to +11.28% (FATE) while the 3-downside ranges from -1.88% (VYGR) to -7.17% (KDNY);

Wednesday’s (10 of 29) incline

Fate Therapeutics (FATE +$8.36 after Tuesday’s +$1.32 and Monday’s +$0.61),
Intellia Therapeutics (NTLA +$8.01 after Tuesday’s +$6.93 and Monday’s +$0.58);
CRISPR Therapeutics (CRSP +$6.65 after Tuesday’s +$4.48 and Monday’s -$0.52);
Alnylam Pharmaceuticals (ALNY +$6.06 after Tuesday’s +$1.33 and Monday’s -$2.45);
Vericel (VCEL +$2.91 after Tuesday’s +$1.59 and Monday’s -$0.59);
Ultragenyx (RARE +$1.80 after Tuesday’s +$3.12 and Monday’s -$1.74);
Sage Therapeutics (SAGE +$1.57 after Tuesday’s +$1.68 and Monday’s -$2.14);
bluebird bio (BLUE +$1.53 after Tuesday’s -$2.32 and Monday’s +$0.96);
Editas Medicine (EDIT +$1.50);
Cellectis SA (CLLS +$1.40 after Tuesday’s -$0.29);

Wednesday’s (3 of 3) decliners:

Chinook Therapeutics (KDNY -$1.20 after Tuesday’s +$1.09 after Monday’s -$1.08);
Voyager Therapeutics (-$0.09);
Biostage (BSTG -$0.035 after Tuesday’s -$0.125 and Monday’s flat at $1.50)

Closing: 2 – ReNeuron (RENE.L), Global Blood Therapeutics (GBT) and 1 - Stemline Therapeutics (STML – acquired)

Sentiment and COVID-19 infections:

As more states expand eligibility rules for who can receive a vaccine - 90% of adults in the U.S. will be eligible for shots by April 19 — the daily pace of vaccinations continues to rise.

Infection cases <Million>: never to forget …

Wednesday 30.21 M cases,
Wednesday’s death rate totaled 548,162 <Johns Hopkins University>

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Wednesday, the IBB closed UP +2.65% and XBI closed up +4.26%

The CBOE Volatility Index (VVIX: INDEX) tracked:

Wednesday was down – 0.21 points or -1.07% at 19.40

Upside volume: low

Wednesday: 6 out of the 29-upside had higher than the 3-month average volume;

Downside volume: low

Wednesday: 1 out of the 3-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

Wednesday’s percentage (%) of the 29-upside were +0.11% (BLFS) to +11.28% (FATE) while the 3-downside ranges from -1.88% (VYGR) to -7.17% (KDNY);

March, the 3^rd month and end of Q1/21:

Wednesday closed positive with 29 advancers, 3 decliners, 2 flats and 1 acquired

Tuesday closed positive with 25 advancers, 9 decliners, 2 flats and 1 acquired

Monday (3/29) closed negative with 6 advancers, 27 decliners, 1 flat and 1 acquired

Friday closed negative with 12 advancers, 20 decliners, 2 flats and 1 acquired

Thursday closed positive with 22 advancers, 11 decliners, 1 flat and 1 acquired

Wednesday closed negative with 1 advancer, 33 decliners and 1 acquired

Tuesday closed negative with 3 advancers, 31 decliners and 1 acquired

Monday (3/22) closed negative with 16 advancers, 18 decliners and 1 acquired

Friday closed positive with 32 advancers, 2 decliners and 1 acquired

Thursday closed negative with 4 advancers, 29 decliners, 1 flat and 1 acquired

Wednesday closed positive with 25 advancers, 8 decliners, 1 flat and 1 acquired

Tuesday closed negative with 4 advancers, 30 decliners and 1 acquired

Monday (3/15) closed positive with 25 advancers, 9 decliners and 1 acquired

Friday closed negative with 12 advancers, 22 decliners and 1 acquired

Thursday closed positive with 28 advancers, 6 decliners and 1 acquired

Wednesday closed neutral with 15 advancers, 15 decliners, 4 flat and x acquired

Tuesday closed positive with 30 advancers, 4 decliners and 1 acquired

Monday (3/8) closed negative with 3 advancers, 30 decliners, 1 flat and 1 acquired

Friday closed positive with 18 advancers, 14 decliners, 2 flats and 1 acquired

Thursday closed negative with 3 advancers, 30 decliners, 1 flat and 1 acquired

Wednesday closed negative with 3 advancers, 30 decliners, 1 flat and 1 acquired

Tuesday closed negative with 8 advancers, 26 decliners and 1 acquired

Monday (3/1) closed positive with 27 advancers, 6 decliners, 1 flat and 1 acquired

The BOTTOM LINE: We were on the winning side of trading today … wild swings have hit the market and could deepen (Thursday week) when pension funds and other big investors conduct their quarter-end rebalancing.

I will be kissing some highs – goodbye; time to profit as new month and Q2 begins pre market close! Market and the sector is still a game of chance …

Who says, one can’t make it as a retail investor … trade it to make it!

“Again, my time horizon for HOLDING an equity is last Friday through Thursday (this week)” – think about that and check the Advance/Decline (A/D line) to VALIDATE my thesis.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.